Federal contract receipt
$117,399,278 from Department of Health and Human Services to PPD DEVELOPMENT LP
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Signals
Full and openLarge awardMulti-year performance
Office of Federal Procurement Policy
Public Spend Intelligence - sledai.com
Award #CONT_AWD_75A50124C00001_7505_-NONE-_-NONE-
Signed2024-08-30
VendorPPD DEVELOPMENT LP
PlaceNC
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Total obligated$117,399,278.00
PoP Start
2023-12-15
PoP End
2030-09-30
COMPETED
Awarded on 2024-08-30
Vendor
PPD DEVELOPMENT LP
Agency
Department of Health and Human Services
Category
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Place
NC
© 2025 Sled AI Inc. All rights reserved.